Products Affected - Description
Antivenin Latrodectus Mactans (Black Widow Spider Antivenin), 00006-4084-00, Merck
Reason for the Shortage
- Merck has low inventory of Antivenin Latrodectus Mactans.
- Merck, working in combination with FDA, announced on July 3, 2014 that the expiration date for Antivenin lot H019984 was extended to January 3, 2015. The packaged Antivenin lot H019984 contains one vial of Antivenin lot 0672105, one vial of sterile diluent lot 0671078, and a 1 mL vial of horse serum for sensitivity testing. The expiration dating for the sterile diluent has not been extended. Discard the sterile diluent and reconstitute the Antivenin vial with 2.5 mL of sterile water for injection.
There are insufficient supplies for usual ordering.
Estimated Resupply Dates
Emergency supplies are available for patients with symptoms due to a bite by the black widow spider within 24 hours of contacting Merck. The company cannot estimate when regular distribution will resume. Do not discard any vials from lot number 0672105 and keep available for use until January 3, 2015.
December 12, 2014; October 13, 2014; August 7, 2014; June 3, 2014; March 12, 2014; December 16, 2013; October 2, 2013; July 18, 2013; May 14, 2013; March 20, 2013; January 28, 2013; November 7, 2012; October 1, 2012; August 8, 2012; May 4, 2012; March 7, 2012; January 10, 2012; November 4, 2011; September 2, 2011; July 26, 2011; June 2, 2011; April 26, 2011; March 16, 2011; February 2, 2011; December 29, 2010; August 5, 2010; May 24, 2010; March 17, 2010; January 25, 2010; December 7, 2009; October 19, 2009; September 2, 2009; May 15, 2009; April 20, 2009; March 5, 2009, University of Utah, Drug Information Service. Copyright 2014, Drug Information Service, University of Utah, Salt Lake City, UT.
This information is provided through the support of Novation to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Novation, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Novation, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Novation, ASHP nor University of Utah endorses or recommends the use of any drug.
« Back to Drug Shortage Product Bulletins